Drug profile · INN
dapagliflozin + sitagliptin
SIDAPVIA 10/100
dapagliflozin + sitagliptin (SIDAPVIA 10/100) is an FDA-listed pharmaceutical active ingredient. Associated with AstraZeneca.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dapagliflozin + sitagliptin
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
dapagliflozin + sitagliptin (SIDAPVIA 10/100) is an FDA-listed pharmaceutical active ingredient. Associated with AstraZeneca.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Frequently asked questions
What is dapagliflozin + sitagliptin?
dapagliflozin + sitagliptin (SIDAPVIA 10/100) is an FDA-listed pharmaceutical active ingredient. Associated with AstraZeneca.
What is the brand name for dapagliflozin + sitagliptin?
SIDAPVIA 10/100 is a marketed brand name for dapagliflozin + sitagliptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.